Evidence map›Paper›PMID 27088321›Full record

ArticleAIDS (London, England)2016

Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans.

Sulggi A Lee, Joel A Mefford, Yong Huang, John S Witte, Jeffrey N Martin, David W Haas, Paul J Mclaren, Taisei Mushiroda, Michiaki Kubo, Helen Byakwaga and 2 more

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Sulggi A LeeaDepartment of Medicine bDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California cDepartment of Medicine, Vanderbilt University School of Medicine dDepartment of Medicine, Meharry Medical College, Nashville, Tennessee, USA eDepartment of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland fRIKEN Center for Genomic Medicine, Kanagawa, Japan gDepartment of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Joel A Mefford
Yong Huang
John S Witte
Jeffrey N Martin
David W Haas
Paul J Mclaren
Taisei Mushiroda
Michiaki Kubo
Helen Byakwaga
Peter W Hunt
Deanna L Kroetz
Apple (Israel) · IL

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
AIDS and Cancer Specimen Resource (ACSR)UM1CA181255 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jeffrey Michael Bethony, Anna Coghill · 2013 to 2026
$56.7M
Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
TB PREVENTION AND HIV IN THE HOMELESS--AN INTERVENTIONR01MH054907 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANGSBERG, DAVID ROY · 1995 to 2014
$20.7M
Pharmacogenomics of HIV TherapyR01AI077505 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HAAS, DAVID W · 2008 to 2025
$12.3M
Specimen Acquisition and Distribution CoreP01AI076174 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LANDAY, ALAN L · 2008 to 2012
$10.9M
GRADUATE RESEARCH TRAINING ON ALCOHOL PROBLEMST32AA007240 · NIAAA · UNIVERSITY OF CALIFORNIA BERKELEY · PI William C. Kerr · 1985 to 2026
$7.5M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
A pharmacogenomics study of HIV latency: the role of PD-1 signalingK23GM112526 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, SULGGI ANGELA · 2014 to 2018
$908k
NCI NIH HHS UM1 CA181255NIAAA NIH HHS L30 AA015293NIAAA NIH HHS T32 AA007240NIAID NIH HHS P01 AI076174NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI077505NIAID NIH HHS R21 AI078774NIAID NIH HHS R56 AI100765NIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI069501NIGMS NIH HHS K23 GM112526NIGMS NIH HHS U01 GM061390NIMH NIH HHS K24 MH087227NIMH NIH HHS R01 MH054907
6 · The paper itself

Abstract

objectivePlasma kynurenine/tryptophan ratio, a biomarker of indoleamine 2,3-dioxygenase-1 (IDO) activity, is a strong independent predictor of mortality in HIV-infected Ugandans initiating antiretroviral therapy (ART) and may play a key role in HIV pathogenesis. We performed a genome-wide study to identify potential host genetic determinants of kynurenine/tryptophan ratio in HIV-infected ART-suppressed Ugandans. DESIGN/

methodsWe performed genome-wide and exome array genotyping and measured plasma kynurenine/tryptophan ratio during the initial 6-12 months of suppressive ART in Ugandans. We evaluated more than 16 million single nucleotide polymorphisms in association with log10 kynurenine/tryptophan ratio using linear mixed models adjusted for cohort, sex, pregnancy, and ancestry.

resultsAmong 597 Ugandans, 62% were woman, median age was 35, median baseline CD4 cell count was 135 cells/μl, and median baseline HIV-1 RNA was 5.1 log10 copies/ml. Several polymorphisms in candidate genes TNF, IFNGR1, and TLR4 were associated with log10 kynurenine/tryptophan ratio (P < 5.0 × 10). An intergenic polymorphism between CSPG5 and ELP6 was genome-wide significant, whereas several others exhibited suggestive associations (P < 5.0 × 10), including genes encoding protein tyrosine phosphatases (PTPRM and PTPRN2) and the vitamin D metabolism gene, CYP24A1. Several of these single nucleotide polymorphisms were associated with markers of inflammation, coagulation, and monocyte activation, but did not replicate in a small US cohort (N = 262; 33% African-American).

conclusionOur findings highlight a potentially important role of IFN-γ, TNF-α, and Toll-like receptor signaling in determining IDO activity and subsequent mortality risk in HIV-infected ART-suppressed Ugandans. These results also identify potential novel pathways involved in IDO immunoregulation. Further studies are needed to confirm these findings in treated HIV-infected populations.

Indexed as

AdultAnti-Retroviral AgentsFemaleHIV InfectionsHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaKynurenineMaleMetabolismPlasmaRisk AssessmentSignal TransductionSurvival AnalysisToll-Like ReceptorsTryptophanAnti-Retroviral AgentsIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaKynurenineToll-Like ReceptorsTryptophanTumor Necrosis Factor-alpha

Identifiers

PMID27088321
PMCPMC4925250
OpenAlexW2342359992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.